According to clinical trial results funded by Cancer Research UK and Stand Up To Cancer, a new approach combining chemoradiotherapy and rectum-preserving surgery allows four in five patients with early-stage rectal cancer to keep their rectum and avoid major operations. Around 4,100 people in England receive an early-stage rectal cancer diagnosis each year, facing standard radical surgery that removes the entire rectum and often leads to permanent colostomy bags and severe bowel, urinary, and sexual side effects.
How the STAR-TREC Trial Changed Early-Stage Rectal Cancer Treatment
Researchers at UCL, the University of Birmingham, and the University of Leeds led the STAR-TREC trial, which recruited over 500 patients across five countries. The study evaluated whether organ-preserving strategies could replace radical surgery for early-stage bowel cancer. According to the findings, patients who underwent five weeks of chemoradiotherapy were significantly less likely to require radical surgery compared to those who received five days of standalone radiotherapy.
Brian, a 69-year-old trial participant from Birmingham, noticed bleeding and changes in bowel habits. Expecting haemorrhoids, an emergency endoscopy instead revealed a suspicious lump inside his rectum. “The diagnosis was totally unexpected,” Brian says, noting that his consultant introduced the STAR-TREC trial soon after. He received five days of intensive radiotherapy with minimal side effects like mild nausea and lower back pain, ultimately avoiding a permanent colostomy bag.
Medical Perspectives on Organ-Preserving Cancer Therapy
David Sebag-Montefiore, co-chief investigator of STAR-TREC and Professor of Clinical Oncology at the University of Leeds, states that these results show how smarter, kinder radiotherapy allows patients to bypass major operations. Michelle Mitchell, Cancer Research UK’s chief executive, notes that the breakthrough could prove life-changing for thousands of individuals diagnosed annually.
Did you know? Around 4,100 people in England are diagnosed with early-stage rectal cancer every year, making large-scale clinical trials essential for discovering less invasive alternatives to standard radical surgery.
Next Steps for Rectal Cancer Research and Patient Care
The research team plans to track trial participants for the next three years to monitor long-term cancer recurrence rates and overall survival. Simon Bach, co-chief investigator and Professor of Colorectal Surgery at UCL, explains that the immediate priority is confirming that these results hold over time before ensuring the approach reaches every eligible patient. For participants like Brian, follow-up CT scans, MRI scans, and endoscopies show no trace of cancer, allowing him to return to traveling and supporting Millwall Football Club.
Frequently Asked Questions
What is the STAR-TREC trial?
The STAR-TREC trial is an international clinical study funded by Cancer Research UK and Stand Up To Cancer that evaluates whether organ-preserving chemoradiotherapy can help early-stage rectal cancer patients avoid radical surgery.
What are the common side effects of standard rectal cancer surgery?
Standard radical surgery removes the whole rectum, frequently resulting in permanent colostomy bags, bowel dysfunction, and urinary and sexual problems.
Who qualifies for the STAR-TREC treatment approach?
The trial focuses on patients diagnosed with early-stage rectal cancer who meet specific clinical criteria for organ preservation.
How successful was the five-week chemoradiotherapy approach?
According to 12-month trial results, five weeks of chemoradiotherapy allowed four in five patients to keep their rectum, avoid major surgery, and maintain a better quality of life.
Join the Conversation: What are your thoughts on the future of organ-preserving cancer treatments? Leave a comment below, explore our related health research articles, or subscribe to our newsletter for the latest updates.